MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 10, 2004; DOI: 10.1124/mol.104.001008


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.001008v1
66/5/1248    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sugita, M.
Right arrow Articles by Shiba, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sugita, M.
Right arrow Articles by Shiba, Y.


Received for publication April 1, 2004.
Revised August 3, 2004.
Accepted for publication August 3, 2004.

Molecular dissection of butyrate action revealed the involvement of MAPK in CFTR biogenesis

Makoto Sugita 1*, Hiroyasu Kongo 1, Yoshiki Shiba 1

1 Hiroshima University

* Address correspondence to: E-mail: sugisan{at}hiroshima-u.ac.jp

Abstract

Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which belongs to the superfamily of ABC transporters and uniquely possesses an additional large cytoplasmic domain (R domain). CFTR inefficiently folds by means of co- and post-translational interactions with the cytosolic chaperones as well as ER lumenal chaperones in the ER. Aberrant folding and defective trafficking of the CFTR protein, which functions as an apical membrane Cl- channel, is the principal cause of cystic fibrosis. Recent data indicated that butyrate improves CFTR trafficking, in part, by regulating molecular chaperones. However, the precise mechanism of butyrate action remains elusive. In the present study, we examine the molecular aspect underlying the butyrate action in CFTR biogenesis, by evaluating the expression and localization of the GFP-tagged CFTR transgenes in Cos7 cells. Our data show that butyrate significantly promoted stability of the ER-located form of GFP-wt- CFTR, followed by an increase in the amount of plasma membrane GFP-wt-CFTR. In contrast, the expression of the R domain deletion mutant, GFP-{Delta}R-CFTR, was slightly increased by butyrate. The butyrate action on wt-CFTR expression was partially blocked by PD98059, a specific inhibitor of MAPKK/MEK which is the upstream activator of ERK/MAPK. Furthermore, activation of ERK/MAPK by coexpression of constitutively active MAPKK/MEK predominantly augmented the expression of wt- CFTR, but not of {Delta}R-CFTR, induced by butyrate. These data suggest that butyrate may facilitate the biogenesis and trafficking of wt-CFTR by requiring the presence of the R domain, and further involving active ERK/MAPK in its biogenesis.


Key words: MAP Kinase, Ion transporters (SERCA, Na/K ATPase, CFTR), Regulation of gene expression, Regulation - post-transcriptional


This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
T. Roque, E. Boncoeur, V. Saint-Criq, E. Bonvin, A. Clement, O. Tabary, and J. Jacquot
Proinflammatory Effect of Sodium 4-Phenylbutyrate in {Delta}F508-Cystic Fibrosis Transmembrane Conductance Regulator Lung Epithelial Cells: Involvement of Extracellular Signal-Regulated Protein Kinase 1/2 and c-Jun-NH2-Terminal Kinase Signaling
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 949 - 956.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics